181 related articles for article (PubMed ID: 27095306)
21. Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study.
Horsmans Y; Zhou J; Liudmila M; Golor G; Shibolet O; Quinlan M; Emotte C; Boss H; Castro H; Sellami D; Preston RA
Clin Pharmacokinet; 2018 Mar; 57(3):345-354. PubMed ID: 28577129
[TBL] [Abstract][Full Text] [Related]
22. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
Li Y; Song Q; Day BW
Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
[TBL] [Abstract][Full Text] [Related]
23. A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study.
Ruiz-Borrego M; Jimenez B; Antolín S; García-Saenz JA; Corral J; Jerez Y; Trigo J; Urruticoechea A; Colom H; Gonzalo N; Muñoz C; Benito S; Caballero R; Bezares S; Carrasco E; Rojo F; Martín M
Invest New Drugs; 2019 Feb; 37(1):98-108. PubMed ID: 29948356
[TBL] [Abstract][Full Text] [Related]
24. Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors.
Minami H; Ando Y; Ma BB; Hsiang Lee J; Momota H; Fujiwara Y; Li L; Fukino K; Ito K; Tajima T; Mori A; Lin CC
Cancer Sci; 2016 Oct; 107(10):1477-1483. PubMed ID: 27467121
[TBL] [Abstract][Full Text] [Related]
25. Recovery of taste organs and sensory function after severe loss from Hedgehog/Smoothened inhibition with cancer drug sonidegib.
Kumari A; Ermilov AN; Grachtchouk M; Dlugosz AA; Allen BL; Bradley RM; Mistretta CM
Proc Natl Acad Sci U S A; 2017 Nov; 114(48):E10369-E10378. PubMed ID: 29133390
[TBL] [Abstract][Full Text] [Related]
26. Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors.
Goldman J; Eckhardt SG; Borad MJ; Curtis KK; Hidalgo M; Calvo E; Ryan DP; Wirth LJ; Parikh A; Partyka J; Faessel H; Gangolli E; Stewart S; Rosen LS; Bowles DW
Clin Cancer Res; 2015 Mar; 21(5):1002-9. PubMed ID: 25501576
[TBL] [Abstract][Full Text] [Related]
27. Dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor sonidegib to manage adverse effects: A retrospective case series.
Villani A; Costa C; Fabbrocini G; Ruggiero A; Scalvenzi M
J Am Acad Dermatol; 2021 Apr; 84(4):e211-e212. PubMed ID: 33301802
[No Abstract] [Full Text] [Related]
28. A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients.
Einolf HJ; Zhou J; Won C; Wang L; Rebello S
Drug Metab Dispos; 2017 Apr; 45(4):361-374. PubMed ID: 28122787
[TBL] [Abstract][Full Text] [Related]
29. Treatment of advanced basal cell carcinoma with sonidegib: perspective from the 30-month update of the BOLT trial.
Chen L; Aria AB; Silapunt S; Lee HH; Migden MR
Future Oncol; 2018 Mar; 14(6):515-525. PubMed ID: 29119833
[TBL] [Abstract][Full Text] [Related]
30. Vismodegib, itraconazole and sonidegib as hedgehog pathway inhibitors and their relative competencies in the treatment of basal cell carcinomas.
Wahid M; Jawed A; Mandal RK; Dar SA; Khan S; Akhter N; Haque S
Crit Rev Oncol Hematol; 2016 Feb; 98():235-41. PubMed ID: 26614022
[TBL] [Abstract][Full Text] [Related]
31. Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma.
Sanmartín O; Llombart B; Carretero Hernández G; Flórez Menéndez Á; Botella-Estrada R; Herrera Ceballos E; Puig S
Actas Dermosifiliogr (Engl Ed); 2021 Apr; 112(4):295-301. PubMed ID: 33197438
[TBL] [Abstract][Full Text] [Related]
32. Rapid and exceptional response to Sonidegib in a patient with multiple locally advanced basal cell carcinomas.
Tarantino V; Zavattaro E; Veronese F; Gironi LC; Savoia P
Anticancer Drugs; 2021 Apr; 32(4):465-468. PubMed ID: 33534224
[TBL] [Abstract][Full Text] [Related]
33. Sonidegib phosphate: new approval for basal cell carcinoma.
Tibes R
Drugs Today (Barc); 2016 May; 52(5):295-303. PubMed ID: 27376162
[TBL] [Abstract][Full Text] [Related]
34. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.
Danial C; Sarin KY; Oro AE; Chang AL
Clin Cancer Res; 2016 Mar; 22(6):1325-9. PubMed ID: 26546616
[TBL] [Abstract][Full Text] [Related]
35. Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers.
Zhou J; Quinlan M; Glenn K; Boss H; Picard F; Castro H; Sellami D
Br J Clin Pharmacol; 2016 Oct; 82(4):1022-9. PubMed ID: 27277189
[TBL] [Abstract][Full Text] [Related]
36. Hedgehog inhibition with the orally bioavailable Smo antagonist LDE225 represses tumor growth and prolongs survival in a transgenic mouse model of islet cell neoplasms.
Fendrich V; Wiese D; Waldmann J; Lauth M; Heverhagen AE; Rehm J; Bartsch DK
Ann Surg; 2011 Nov; 254(5):818-23; discussion 823. PubMed ID: 22042473
[TBL] [Abstract][Full Text] [Related]
37. Noninvasive monitoring of basal cell carcinomas treated with systemic hedgehog inhibitors: pseudocysts as a sign of tumor regression.
Maier T; Kulichova D; Ruzicka T; Berking C
J Am Acad Dermatol; 2014 Oct; 71(4):725-30. PubMed ID: 24928708
[TBL] [Abstract][Full Text] [Related]
38. The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours.
Pooler DB; Ness DB; Sarantopoulos J; Squittieri N; Ravichandran S; Britten CD; Amaravadi RK; Vaishampayan U; LoRusso P; Shapiro GI; Olszanski AJ; Perez R; Gutierrez M; O'Rourke MA; Chung V; Lee JJ; Lewis LD
Br J Clin Pharmacol; 2021 Mar; 87(3):1291-1302. PubMed ID: 32736411
[TBL] [Abstract][Full Text] [Related]
39. An exploratory open-label, investigator-initiated study to evaluate the efficacy and safety of combination sonidegib and buparlisib for advanced basal cell carcinomas.
Tran DC; Moffat A; Brotherton R; Pague A; Zhu GA; Chang ALS
J Am Acad Dermatol; 2018 May; 78(5):1011-1013.e3. PubMed ID: 29175429
[No Abstract] [Full Text] [Related]
40. Sonidegib for the treatment of advanced basal cell carcinoma.
Ramelyte E; Amann VC; Dummer R
Expert Opin Pharmacother; 2016 Oct; 17(14):1963-8. PubMed ID: 27538055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]